GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes

Inflammation

Volumn 38, Issue 3, 2015, Pages 1357-1363

  Dungan, Kathleen ^a   Binkley, Philip ^a,b   Osei, Kwame ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

acute phase response; cytokine; GlycA; glycoprotein; type 2 diabetes

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLYCOPROTEIN; HEMOGLOBIN; IL6 PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

BLOOD; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSPECTIVE STUDY;

ACUTE-PHASE PROTEINS; BIOMARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPROTEINS; HEMOGLOBINS; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939934809     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0107-8     Document Type: Article

References (34)

1. Fraze, T.K. (Thomson Reuters), Jiang, H.J. (AHRQ), and Burgess, J. 2008. (Thomson Reuters). Hospital Stays for Patients with Diabetes. HCUP Statistical Brief #93. August 2010. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb93.pdf.
2. Umpierrez, G.E., R. Hellman, M.T. Korytkowski, M. Kosiborod, G.A. Maynard, V.M. Montori, J.J. Seley, and G. Van den Berghe. 2012. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline; Endocrine Society. Journal of Clinical Endocrinology and Metabolism 97(1): 16–38.
3. Umpierrez, G.E., S.D. Isaacs, N. Bazargan, X. You, L.M. Thaler, and A.E. Kitabchi. 2002. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. Journal of Clinical Endocrinology and Metabolism 87(3): 978–82.
4. Menzin, J., J.R. Korn, J. Cohen, F. Lobo, B. Zhang, M. Friedman, and P.J. Neumann. 2010. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. Journal of Managed Care Pharmacy 16(4): 264–75.
5. Falciglia, M., R.W. Freyberg, P.L. Almenoff, D.A. D’Alessio, and M.L. Render. 2009. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Critical Care Medicine 37(12): 3001–9.
6. Pickup, J.C., and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241–8.
7. Clement, S., S.S. Braithwaite, M.F. Magee, A. Ahmann, E.P. Smith, R.G. Schafer, I.B. Hirsch, and American Diabetes Association Diabetes in Hospitals Writing Committee. 2004. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27(2): 553–91.
8. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340: 448–54.
9. Ceciliani, F., and V. Pocacqua. 2007. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Current Protein and Peptide Science 8: 91–108.
10. Dijk, W., G. Turner, and A. Mackiewicz. 1994. Changes in glycosylation of acute-phase proteins in health and disease: occurrence, regulation and function. Glycoconjugate Journal 1: 5–14.
11. Bell, J.D., J.C. Brown, J.K. Nicholson, and P.J. Sadler. 1987. Assignment of resonances for ‘acute-phase’ glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Letters 215: 311–5.
12. Otvos J, Shalaurova I, Wolak-Dinsmore J, Matyus S. 2013. GlycA and GlycB: novel NMR markers of systemic inflammation. American Association of Clinical Chemistry Poster #B-255.
13. Akinkuolie A, Pradhan AD, Ridker PM, Mora S. 2013. Novel protein glycan derived biomarker is associated with incident diabetes. American Heart Association Poster 18807.
14. Akinkuolie A.O., Buring J.E., Ridker P.M., Mora S. 2013. Novel protein glycan derived marker of systemic inflammation is associated with incident cardiovascular disease. American Heart Association, Poster 18739.
15. Kriat, M., J. Vion-Dury, R. Fayre, D. Maraninchi, J.R. Harlé, S. Confort-Gouny, M. Sciaky, E. Fontanarava, P. Viout, and P.J. Cozzone. 1991. Variations of plasma sialic acid and N-acetylglucosamine levels in cancer, inflammatory diseases and bone marrow transplantation: a proton NMR spectroscopy study. Biochimie 73: 99–104.
16. Dungan, K.M., C. Sagrilla, M. Abdel-Rasoul, and K. Osei. 2013. Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes. Diabetes Care 36(11): 3476–82.
17. Dungan K.M., Osei K., Gaillard T., Moore J., Binkley P. 2014. A comparison of continuous intravenous insulin and subcutaneous insulin among patients with type 2 diabetes and congestive heart failure exacerbation. Diabetes Metab Res Rev in press.
18. Modification of Diet in Renal Disease Study Group. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine 130(6): 461–70.
19. Braunwald, E. 2008. Biomarkers in heart failure. New England Journal of Medicine 358: 2148–2159.
20. Burger, A.J., and D. Aronson. 2001. Blunted sympathetic response in diabetic patients with decompensated congestive heart failure. International Journal of Cardiology 81: 243–249.
21. Romeo, R., C. Scalisi, L. Tafuri, A. Romeo, D. Maugeri, and R. Sorace. 2010. Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics. Archives of Gerontology and Geriatrics 50(1): 101–4.
22. Jankowska, E.A., P. Ponikowski, M.F. Piepoli, W. Banasiak, S.D. Anker, and P.A. Poole-Wilson. 2006. Autonomic imbalance and immune activation in chronic heart failure—pathophysiological links. Cardiovascular Research 70: 434–445.
23. Gruzdeva, O., E. Uchasova, Y. Dyleva, E. Belik, E. Shurygina, and O. Barbarash. 2013. Insulin resistance and inflammation markers in myocardial infarction. Journal of Inflammation Research 6: 83–90.
24. Heo, J.M., J.H. Park, J.H. Kim, S.H. You, J.S. Kim, C.M. Ahn, S.J. Hong, K.H. Shin, and D.S. Lim. 2012. Comparison of inflammatory markers between diabetic and nondiabetic ST segment elevation myocardial infarction. Journal of Cardiology 60(3): 204–9.
25. Liao, M.T., C.C. Sung, K.C. Hung, C.C. Wu, L. Lo, and K.C. Lu. 2012. Insulin resistance in patients with chronic kidney disease. Journal of Biomedicine and Biotechnology 2012: 691369.
26. Karavanaki, K., K. Kakleas, S. Georga, A. Bartzeliotou, G. Mavropoulos, M. Tsouvalas, A. Vogiatzi, I. Papassotiriou, and C. Karayianni. 2012. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis. Clinical Biochemistry 45(16–17): 1383–8.
27. Turina, M., D.E. Fry, and H.C. Polk Jr. 2005. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Critical Care Medicine 33(7): 1624–33.
28. Fantin Sde, S., M.V. Wainstein, C.A. Polanczyk, P. Ledur, C.M. Lazzari, C. Klein, F.S. Hackenhaar, M.S. Benfato, and B.D. Schaan. 2011. Inflammatory and oxidative stress markers after intravenous insulin in percutaneous coronary intervention with stent in type 2 diabetes mellitus: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 96(2): 478–85.
29. Bree, F., G. Houin, J. Barre, J.L. Moretti, V. Wirquin, and J.P. Tillement. 1986. Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein. Clinical Pharmacokinetics 11(4): 336–342.
30. Jones, E.A., J. Vergalla, C.J. Steer, P.R. Bradley-Moore, and J.M. Vierling. 1978. Metabolism of intact and desialylated alpha 1-antitrypsin. Clinical Science and Molecular Medicine 55(2): 139–48.
31. Kormoczi, G.F., M.D. Saemann, C. Buchta, et al. 2006. Influence of clinical factors on the haemolysis marker haptoglobin. European Journal of Clinical Investigation 36: 202–209.
32. Ho, K.M., and J. Lipman. 2009. An update on C-reactive protein for intensivists. Anaesthesia and Intensive Care 37(2): 234–41.
33. Sidhu, R.S., and A.P. Bollon. 1993. Tumor necrosis factor activities and cancer therapy—a perspective. Pharmacology and Therapeutics 57(1): 79–128.
34. Oda, S., H. Hirasawa, H. Shiga, K. Nakanishi, K. Matsuda, and M. Nakamua. 2005. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 29(4): 169–75.